Novartis CEO joins Anthropic Board of Directors, with independent trusts appointing the majority of seats for the first time

ME News Report, April 14 (UTC+8), according to 1M AI News monitoring, Anthropic announced that Novartis CEO Vas Narasimhan, a global pharmaceutical giant, has joined its board of directors, appointed by the company’s Long-Term Benefit Trust. Following this appointment, the trust-appointed director holds the majority seat in the seven-member board for the first time. Anthropic’s Long-Term Benefit Trust is an independent organization; its members have no financial interests in Anthropic, and its responsibility is to ensure that corporate governance balances commercial success with public welfare missions. Currently, the board has seven members: Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, Chris Liddell, and Narasimhan. Narasimhan is a medical scientist who led the development and approval of over 35 new drugs during his tenure as Novartis CEO. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis projects in India, Africa, and South America, and is now a member of the U.S. National Academy of Medicine. Daniela Amodei, co-founder and president of Anthropic, stated that Narasimhan’s experience in one of the most heavily regulated industries in the world, bringing powerful new technologies to market safely and at scale, is exactly what Anthropic does every day. (Source: BlockBeats)